LY5
| Code | Size | Price |
|---|
| TAR-T24423-50mg | 50mg | £837.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T24423-100mg | 100mg | £1,227.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
LY5 is an inhibitor of STAT3 that acts by inhibiting cell viability, cell migration, and angiogenesis in medulloblastoma cells.
CAS:
1436382-03-4
Formula:
C15H11N3O4S
Molecular Weight:
329.33
Purity:
0.98
SMILES:
NS(=O)(=O)c1cccc2C(=O)C(Nc3cccnc3)=CC(=O)c12
References
1. Qiao X, Rao P, Zhang Y, Liu L, Pang M, Wang H, Hu M, Tian X, Zhang J, Zhao Y, Wang XM, Wang C, Yu H, Guo F, Cao Q, Wang Y, Wang YM, Zhang GY, Lee VW, Alexander SI, Zheng G, Harris DCH. Redirecting TGF-? Signaling through the ?-Catenin/Foxo Complex Prevents Kidney Fibrosis. J Am Soc Nephrol. 2018 Feb;29(2):557-570. doi: 10.1681/ASN.2016121362. Epub 2017 Nov 27. PubMed PMID: 29180394; PubMed Central PMCID: PMC5791062.
2. Chiba Y, Mizoguchi I, Furusawa J, Hasegawa H, Ohashi M, Xu M, Owaki T, Yoshimoto T. Interleukin-27 Exerts Its Antitumor Effects by Promoting Differentiation of Hematopoietic Stem Cells to M1 Macrophages. Cancer Res. 2018 Jan 1;78(1):182-194. doi: 10.1158/0008-5472.CAN-17-0960. Epub 2017 Nov 1. PubMed PMID: 29093008.
3. Yu PY, Gardner HL, Roberts R, Cam H, Hariharan S, Ren L, LeBlanc AK, Xiao H, Lin J, Guttridge DC, Mo X, Bennett CE, Coss CC, Ling Y, Phelps MA, Houghton P, London CA. Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma. PLoS One. 2017 Jul 27;12(7):e0181885. doi: 10.1371/journal.pone.0181885. eCollection 2017. PubMed PMID: 28750090; PubMed Central PMCID: PMC5531494.
4. Wang Y, Huang D, Chen KY, Cui M, Wang W, Huang X, Awadellah A, Li Q, Friedman A, Xin WW, Di Martino L, Cominelli F, Miron A, Chan R, Fox JG, Xu Y, Shen X, Kalady MF, Markowitz S, Maillard I, Lowe JB, Xin W, Zhou L. Fucosylation Deficiency in Mice Leads to Colitis and Adenocarcinoma. Gastroenterology. 2017 Jan;152(1):193-205.e10. doi: 10.1053/j.gastro.2016.09.004. Epub 2016 Sep 14. PubMed PMID: 27639802; PubMed Central PMCID: PMC5164974.